Medison Pharma

Medison Pharma was founded in 2017 by Shelly Maizel-Golan, who has served as CEO since the company's inception. The founding thesis was rooted in a structural market failure: global pharmaceutical companies with already-approved, often breakthrough therapies were systematically bypassing small and mid-size markets because the cost of building local regulatory and commercial infrastructure exceeded the projected revenue. Maizel-Golan, drawing on over two decades of international pharma experience, recognized that patients in approximately 70 countries were being denied access to therapies already approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Medison Pharma's global headquarters is located in Tel Aviv, Israel. All senior leadership, global business development, regulatory strategy, and financial operations are managed from that single Israeli location. The company does not maintain additional Israeli offices in Haifa, Beer Sheva, or Jerusalem; its Israel footprint is concentrated in Tel Aviv. Outside of Israel, Medison maintains local commercial and regulatory representatives in the dozens of markets where it operates, spanning Europe, Latin America, the Middle East, and parts of Asia-Pacific.

Medison Pharma is a private company and is not listed on any public stock exchange as of late 2025. The company's most prominent financing event was a $150 million funding round closed in January 2022, one of the largest single rounds raised by an Israeli healthcare company that year. OrbiMed, a New York-based healthcare-focused investment firm with over $17 billion in assets under management, led the round. While the post-money valuation was not officially disclosed, financial press coverage at the time placed the company in unicorn territory, implying a valuation exceeding $1 billion.

Medison Pharma employs more than 500 people globally. The exact split between Israel and international markets has not been publicly disclosed with precision, but estimates based on available press coverage suggest approximately 150 to 200 employees are based in Tel Aviv. The remaining workforce is distributed across the company's active commercial markets, where local medical, regulatory, and sales teams operate country by country.

Medison Pharma is a specialty pharmaceutical commercialization company that partners with global pharma corporations to bring oncology, rare disease, and women's health therapies to mid-size and emerging markets that the originating companies do not serve directly. The single most significant corporate development in the company's last 12 months has been the continued deepening of portfolio partnerships with global pharmaceutical companies including AstraZeneca and Pfizer, alongside a push into the cell and gene therapy space — a high-growth segment where Medison announced expanded commercialization activities in 2023. Medison Pharma is not a subsidiary of any parent company; it is an independently operated entity backed by external institutional investors.

Medison Pharma's primary service offering is what the company internally describes as Agile Commercialization — a proprietary model in which Medison assumes full responsibility for the regulatory submission, market authorization, pricing negotiation with national health systems, supply chain management, and local commercial execution of approved therapies on behalf of originating pharmaceutical companies. Rather than requiring a Big Pharma partner to establish a legal entity, hire a local commercial team, and navigate country-specific regulatory submissions independently, Medison absorbs all of that complexity in exchange for a revenue-sharing arrangement over the life of the agreement.

The specific problem Medison addresses is rooted in a structural economics issue within global pharma commercialization. Companies such as Roche, AstraZeneca, Merck, and Pfizer allocate commercial expansion resources by market size. Countries with populations under 10 million, or nations with public health systems that compress reimbursement prices, fall below the internal return-on-investment threshold required to justify a direct commercial presence. As a result, patients in countries such as Israel, Greece, Slovakia, Colombia, and Morocco often wait years longer than patients in the United States or Germany to access therapies that already carry FDA and EMA approval. Medison's entire business model exists to close this access gap profitably — for both itself and its pharma partners.

The buyers of Medison's services are the Business Development, Licensing, and International Commercial divisions of large global pharmaceutical companies. Medison does not sell to hospitals, physicians, or patients directly — those are the downstream beneficiaries, not the contracting parties. The company's target counterpart within a pharma partner is typically the VP of International Business Development or the Chief Commercial Officer of markets outside the US and the five largest EU economies. Every deal Medison signs is a multi-year commercialization partnership agreement, not a transactional sale.

Medison's sales model is entirely sales-led and relationship-driven. There is no self-serve component, no freemium tier, and no digital product marketplace. Senior business development executives at Medison cultivate multi-year relationships with pharma business development counterparts, and deal cycles can last 12 to 24 months from first conversation to signed contract. The company has no presence on AWS Marketplace, Salesforce AppExchange, or any SaaS distribution channel.

Medison's pricing and revenue model is not publicly disclosed in full. However, industry knowledge and available press coverage indicate that the company operates on a revenue-sharing basis — taking a percentage of net sales of each partnered product in each territory — combined with milestone payments tied to specific regulatory and commercial events such as local market authorization approval, first patient treated, and annual sales thresholds. The company does not charge flat consulting fees or per-seat software prices.

Medison's primary competitive moat is its accumulated regulatory infrastructure across 70 markets — an asset that has been built over eight years and cannot be quickly replicated. The company has navigated regulatory submissions with health authorities ranging from the European Medicines Agency to the Israeli Ministry of Health, the Brazilian ANVISA, and agencies across Southeast Asia. This cumulative institutional knowledge, combined with established relationships with local key opinion leaders and national reimbursement committees, represents a durable barrier to entry.

On the technology side, Medison is fundamentally an operations and services company rather than a software development organization. Beginning in 2022-2023, the company began investing in internal digital tooling to manage regulatory submission tracking, market authorization status monitoring, and supply chain logistics across its 70 active markets. These internal tools are designed to replace manual spreadsheet-based workflows and are not commercialized externally.

Medison's core offering is its Integrated Commercialization Service — a bundled, end-to-end operational capability that encompasses regulatory filing and approval management, pricing and reimbursement negotiation with national payors, medical affairs management including key opinion leader engagement, distribution and supply chain logistics, local sales force deployment and training, and post-market pharmacovigilance reporting as required by each market's health authority. This is not a software product; it is a managed service delivered by country-level teams operating under Medison's centralized strategic direction.

A significant adjacent service offering is Early Access Programs (EAP), also called Compassionate Use or Named Patient Programs in various regulatory jurisdictions. Under these programs, Medison manages the administrative and regulatory process that allows specific patients — typically those with serious or life-threatening conditions — to receive a therapy before it has received formal market authorization in their country. EAPs allow Medison's pharma partners to generate early commercial revenue and real-world evidence data, and they allow Medison itself to establish a market presence and build reimbursement dossiers before full approval.

In 2023, Medison publicly announced the expansion of its service portfolio to include cell and gene therapy commercialization — specifically targeting the logistical and regulatory complexity involved in delivering autologous CAR-T therapies (such as Novartis's Kymriah and Bristol Myers Squibb's Breyanzi) to markets outside North America and Western Europe. Cell and gene therapies require hospital-level administration, specialized cold chain logistics, and country-by-country certification of treatment centers, making Medison's operational infrastructure particularly well-suited to this segment.

No products have been sunset or discontinued, as Medison's service model is structured around multi-year agreements rather than single-version software products. It is possible that specific commercialization agreements with pharma partners have expired or not been renewed, but such events have not been reported in the press.

Medison does not appear on any software platform marketplace such as AWS Marketplace or Snowflake Native Apps, as it is not a software vendor. All partnerships are established through direct commercial negotiation and legal agreement.

Regarding quality and compliance certifications, Medison operates under the Good Distribution Practice (GDP) standards required for pharmaceutical supply chain management, and its country-level operations are subject to inspection by local health authorities in each market where it holds a distribution license. No SOC 2 Type II, FedRAMP, or ISO 27001 certifications have been publicly disclosed by the company, which is consistent with its profile as a pharma services firm rather than a cloud software provider.

Medison's most directly comparable competitor in the specialty pharma commercialization space is Atnahs Pharma UK, a British company that acquires the rights to established, off-patent pharmaceutical products in European markets and manages their commercial lifecycle independently. The critical structural difference is that Atnahs acquires outright ownership of commercial rights, while Medison operates through revenue-sharing partnerships without acquiring the underlying intellectual property. This means Medison carries lower financial risk per deal but also potentially captures less upside per product. Atnahs is also focused almost exclusively on Western and Central Europe, while Medison's portfolio spans a more geographically diverse set of markets including the Middle East, Latin America, and Eastern Europe.

A second notable competitor is Acino International, a Swiss-based specialty pharmaceutical company that operates a model of acquiring and commercializing branded pharmaceutical products across emerging markets in Asia, Africa, and Latin America. Acino competes with Medison in certain overlapping geographies — particularly in the Middle East and North Africa region — but its model leans more toward asset acquisition than partnership, which again distinguishes it structurally from Medison's Agile Commercialization approach.

Medison is not evaluated in any Gartner Magic Quadrant or Forrester Wave analysis, as those analyst frameworks apply to software and technology vendors rather than pharmaceutical services companies. The appropriate competitive intelligence frameworks for Medison are pharma industry publications such as those produced by IQVIA, EvaluatePharma, and GlobalData.

From a pricing and positioning standpoint, Medison operates at the premium end of the commercialization partnership market. The company targets relationships with Tier-1 global pharmaceutical companies — those with drugs that carry a meaningful clinical differentiation and a real commercial opportunity in the target markets — rather than competing on low-cost services for generic or off-patent product manufacturers.

The most publicly notable customer win in Medison's history was the 2021 commercialization agreement with AstraZeneca covering oncology products across approximately 15 markets where AstraZeneca lacked a direct commercial presence. This anchor agreement was cited in the context of the January 2022 $150 million fundraising round, suggesting that the AstraZeneca partnership was a material factor in the company's valuation at the time of that financing.

Medison's overall trajectory as of late 2025 is one of expansion. Two structural tailwinds are driving this: first, increasing regulatory and public pressure on global pharmaceutical companies to demonstrate broader geographic access to their therapies as a condition of pricing negotiations in the US and Europe; second, the proliferation of orphan drug designations and rare disease therapies — a category where global patient populations are small but geographically dispersed, making Medison's multi-market model particularly efficient for the originating pharma company. The company has not been acquired by any third party and has not itself made any publicly disclosed acquisitions of other companies.

Medison Pharma's entire Israeli footprint is concentrated in Tel Aviv, which serves as the company's global headquarters. No secondary offices have been reported in Herzliya, Petah Tikva, Ramat Gan, Haifa, Beer Sheva, or Jerusalem. The Tel Aviv location houses the company's executive leadership team, global business development and licensing functions, regulatory affairs leadership, medical affairs, finance, and human resources — in short, all central corporate functions that oversee the company's 70-country operational network.

Of the company's 500-plus global employees, approximately 150 to 200 are estimated to be based in Israel. The functions located in Israel are overwhelmingly strategic and managerial rather than technical in the engineering sense: business development directors, regulatory affairs specialists, market access analysts, medical affairs managers, legal counsel, and corporate finance. Local country-level commercial staff — the medical science liaisons, sales representatives, and local regulatory coordinators who interact daily with physicians and health authorities — are hired in-country and do not sit in Israel.

In 2022, following the close of the $150 million OrbiMed-led financing round, Medison undertook a deliberate headcount expansion in Tel Aviv, adding senior business development and operational leadership roles to support the planned geographic and portfolio expansion. No downsizing or office relocation was reported in 2023 or 2024 — the company's trajectory through this period was one of cautious growth rather than the contraction seen at many Israeli tech companies during the same period of global macroeconomic tightening.

Medison's founder and CEO Shelly Maizel-Golan is Israeli, and her career prior to founding Medison in 2017 included senior commercial and licensing roles at major international pharmaceutical companies. Several of the company's other senior executives are also Israeli nationals, including members of the business development leadership team who manage relationships with global pharma partners. The company's executive bench is drawn from the Israeli and international pharma industry rather than from the Israeli technology startup ecosystem.

In Israel, Medison typically hires for roles including Business Development Manager with international pharma deal experience, Regulatory Affairs Specialist with EMA and ICH submission expertise, Market Access and Reimbursement Analysts, Medical Affairs Managers, and Finance and Operations professionals. Notably absent from the company's typical Israel hiring profile are software engineering roles — backend, machine learning, DevOps, and product management positions of the sort common at Israeli SaaS or cybersecurity companies. Medison is a pharma services company and recruits accordingly.

OrbiMed, the lead investor in Medison's 2022 round, is a US-based fund and not an Israeli venture capital firm. The company has not publicly disclosed participation from Israeli VCs such as Pitango, Viola, or OurCrowd in its cap table. Medison has received positive coverage and recognition from IATI (Israel Advanced Technology Industries), the umbrella organization for Israel's technology and life sciences sector, and has been featured in discussions about Israel's growing presence in global life sciences beyond pure biotech.

Unlike many of Israel's most prominent technology companies — Check Point, Wix, and CyberArk among them — Medison does not have a publicly known pipeline from IDF intelligence units such as Unit 8200 or Unit 81. The company's hiring culture draws from international pharma experience, clinical and regulatory expertise, and business development backgrounds rather than from the signals intelligence and software engineering pipeline that feeds Israel's cybersecurity and enterprise tech ecosystem. This is a meaningful differentiator for candidates evaluating company culture: Medison operates more like a mid-size European specialty pharma company than a Tel Aviv software startup.